Curing patients of cancer is the primary goal of clinical oncologists. The successful treatment of some cancers, notably Hodgkin's disease, Wilms' tumor, acut<:: lymphocytic leukemia, choriocarcinoma, and Burkitt's lymphoma, has led to an increasing number of long-term survivors. Although the acute toxicities of aggressive cancer therapy for a devastating group of diseases are well known, the delayed complications have only recently been recognized. Growth retardation, intellectual impairment, and abnormalities of the cardiovascular, excretory, endocrine, nervous, and respiratory systems are examples of these delayed complications (1, 2) .
Second malignant neoplasms caused by cancer therapy are also among the delayed complications. The oncogenicity of radiation used in the therapy of benign and malignant diseases has been known for several decades (3) . During the last decade, the carcinogenicity of many of the .cancer chemotherapeutic drugs has become recognized in both the laboratory and the clinic (table I) , and comprehensive reviews have been recently published (4) (5) (6) .
The most common concatenation between chemicals that are both anticancer drugs and carcinogens is the electrophilic properties of their active forms (text- fig.  I ). Electrophilic reactants, formed by spontaneous and/ or enzymatic activation, damage cells partly by binding to nucleophilic cellular macromolecules, including DNA. In general, drugs that bind tightly to DNA, e.g., alkylating agents, are carcinogenic, and those that do not, e.g., antimetabolites, are not carcinogenic. The cellular consequences arising from this damage are multiple. In patients with cancer, damage occurs in both neoplastic and normal cells. Lethal damage is the desired effect in neoplastic cells; however, normal cells may also be killed. If the nonlethal damage in the normal cells can be faithfully repaired, they will return to normal. If the cellular damage cannot be repaired, then malignant transformation and/or mutation may occur; the remarkable progress in the definition of the metabolic activation of chemical carcinogens, the highly stereospecific interactions with cell macromolecules, the phenotypic properties of transformed cells, and the multistage progression of the transformed cell to an invasive tumor have been recently reviewed (8, 9) .
The delayed complications of cancer therapy in children are especially important. These treated children have the potential of a normal life-span. Unfortunately, they may be more susceptible than are adults to the oncogenic effects of cancer chemotherapeutic agents. At a given total dose level, age at first exposure to chemical carcinogens has been shown in some cases to be an important risk factor in experimental studies and in epidemiologic investigations in 275 humans. For example, teenagers may have an increased risk of bronchogenic carcinoma caused by cigarette smoke and of bladder cancer caused by aromatic amines when compared to risks of older individuals (10, 11) .
A long latency period exists between initial exposure to a carcinogenic agent and clinical evidence of human cancer. Leukemia induced by radiation and/or chemicals tends to occur sooner than carcinoma caused by carcinogens (6, 12) . On the basis of past experience, the latency period of carcinomas caused by anticancer drugs will be several decades but will still be within the life-span of the long-term survivors of childhood cancers. These survivors may also be at increased risk to known occupational and personal carcinogenic hazards, such as cigarette smoke. Synergistic interactions between Gccupational carcinogens and cigarette smoke are known (13, 14) . Finally, survivors of childhood cancers may be more susceptible to carcinogens than are individuals who have never had cancer because the permissive host determinants that allowed the first cancer to progress from a transformed cell are still present.
Although past experience allows us to speculate, many questions remain to be specifically answered in this population of patients. a) What are the incidences, latency periods, anatomic sites, and biologic properties of the second malignant neoplasms caused by cancer therapy? b) Can we identify the drugs and the combinations of drugs that are the most hazardous? c) Can we identify the doses and types of radiation and combinations between radiotherapeutic and chemotherapeutic agents that are the most hazardous? d) Which patients will be the most susceptible to the oncogenic complications of cancer therapy? e) Will patients cured of their first cancer with oncogenic drugs and/or radiation be more susceptible to occupational and environmental carcinogens? f) Will the therapy-induced cancers be responsive to cancer ther- demiologic and laboratory investigations are needed. Laboratory studies have shown that the multiple effects of anticancer drugs include chromosome aberrations, mutations, and malignant transformation in cultured cells (15, 16) , and causation of cancer in both rodents and primates (4). Retrospective epidemiologic investigations, such as case-control studies, are being conducted on selected populations of patients and have already yielded interesting results. Combination therapy with actinomycin D and radiation is associated· with a decrease in the incidence of second cancers in children with Wilms' tumor when compared to the incidence of second cancers in children treated with only radiation (17) . In contrast, combined modality therapy for Hodgkin's disease may have a greater incidence of oncogenic complications than that found in patients receiving either chemotherapy or radiotherapy (18, 19) . Although the incidence of iatrogenic cancer in children cured of their initial neoplasm is not yet known, preliminary data suggest that the 20-year cumulative probability of second cancers in children surviving 5 years or more is 8-16% (20) . Many of these patients had been treated with orthovoltage radiation, which may be inore hazardous than the currently used megavoltage radiation (21) . Evidence of iatrogenic cancer caused by chemotherapeutic agents alone has accumulated in the recent literature in the form of both case reports and epidemiologic studies (4, (22) (23) (24) . Most of these reported second malignant neoplasms have been leukemias, which may reflect the apparently shorter latency period for leukemia when compared to that required for chemically induced carCInomas. Due to the inherent limitations of retrospective epidemiologic studies, prospective investigations are essential. For example, the Late Effects Study Group is investigating the survivors of childhood cancer (25) . Prospective studies of adult populations are also being conducted by the Radiation Therapy Oncology Group and by several other groups cooperating with the Office of the Director, the Division of Cancer Treatment, and the Environmental Epidemiology Branch, Division of Cancer Cause and Prevention, National Cancer Institute.
The implications of the epidemiologic studies are multiple. For the patients with cancer, the findings could lead to equally effective therapy with noncarcinogenic agents. When an alternative therapy is not available, increased surveillance of the patients at risk and prophylactic therapy could minimize the delayed complications, including second cancers. Because radiation and oncogenic drugs are still being used to treat benign diseases (26) , the findings might further discourage the use of these hazardous therapeutic agents except in life-threatening circumstances.
In my opinion, the benefits of cancer therapy greatly outweigh the risks of oncogenic complications. However, guidelines for the use of carcinogenic drugs and/or radiation as an adjunct to surgical treatment of cancer should be continually reevaluated on the basis of new data. Furthermore, physicians who are informed of the possible delayed complications of cancer therapy should devote additional effort to the careful and long-term follow-up of patients cured of cancer. The fact that we are now directing attention to the delayed complications in survivors of cancer attests to the success of therapy and to the increasing maturity of the field of clinical oncology.
